华海药业：注射用阿糖胞苷获得药品补充申请批准通知书

Core Viewpoint - Huahai Pharmaceutical (600521.SH) has received approval from the National Medical Products Administration for a supplemental application for injectable Ara-C, adding a new specification of 0.1g to the already approved 0.5g version [1] Group 1 - The newly approved injectable Ara-C is indicated for the induction and maintenance treatment of acute non-lymphocytic leukemia in adults and children [1] - The product also shows efficacy in treating other types of leukemia, such as acute lymphocytic leukemia and chronic myeloid leukemia (blast crisis) [1] - Injectable Ara-C can be used alone or in combination with other antitumor drugs, with improved efficacy observed in combination therapy [1]